Role of hepcidin as main regulator of iron metabolism in differential diagnosis of iron deficiency syndromes in cancer patients with colorectal cancer
A study was made of the main metabolites of ferrokinetics (hepcidin 25, interleukin 6, soluble transferrin receptors, ferritin, erythropoietin) for the differential diagnosis of iron deficiency syndromes (AIN). 62 patients with colorectal cancer were examined before treatment: 35 men and 27 women. Age from 31 to 89 (61.5 ± 1.7) years. Three types of anemia are distinguished. 21 people - with iron deficiency (IDA), 23 people with iron deficiency erythropoiesis (ZHDE) and with functional iron deficiency (FJD) - 18 people. Microcytosis and hypohromia of erythrocytes were characteristic for all types of anemia. The concentration of RF, HP25, IL-6 was reduced in patients with IDA and significantly increased in the group with PDJ in comparison with the control. In contrast to IDA, a high level of RF was noted in patients with ZHDE. The indicators of rRTF exceeded the upper limit of the norm in all 3 groups. EPO analysis showed that lower production was observed in all (100 %) patients with FJD, and therefore in patients with a common tumor process (stage III-IV), to a lesser extent in patients with IDA and ZHDE. Further investigation of the expression of GP25, IL-6 is especially important in the differential diagnosis of AZN in combination with IDA and PDJ, since the treatment is fundamentally different. The prospect is a pathogenetic approach to the treatment of AZN in cancer patients using anti-hepatic drugs based on antibodies to the hormone, inhibitors and blockers of its expression under the control of the concentration of GP25 and, possibly, IL-6.